Patents by Inventor Felix Theeuwes

Felix Theeuwes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230372361
    Abstract: Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 23, 2023
    Inventors: Shunlin Ren, Yaping Wang, WeiQi Lin, James E. Brown, Felix Theeuwes
  • Publication number: 20230310458
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Application
    Filed: February 28, 2023
    Publication date: October 5, 2023
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Publication number: 20230218639
    Abstract: Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease. In some instances, methods include treating an addiction to a drug, such as alcohol addiction, cocaine addiction or amphetamine addiction.
    Type: Application
    Filed: June 25, 2021
    Publication date: July 13, 2023
    Applicant: Virginia Commonwealth University
    Inventors: Shunlin Ren, Yaping Wang, WeiQi Lin, James E. Brown, Felix Theeuwes
  • Publication number: 20230165964
    Abstract: The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.
    Type: Application
    Filed: November 8, 2022
    Publication date: June 1, 2023
    Inventors: Michael Sekar, Felix Theeuwes, Keith E Branham, John W Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
  • Publication number: 20230146925
    Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
    Type: Application
    Filed: January 4, 2023
    Publication date: May 11, 2023
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Felix THEEUWES, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
  • Patent number: 11612609
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 28, 2023
    Assignees: Durect Corporation, Virginia Commonwealth University
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Patent number: 11529420
    Abstract: The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: December 20, 2022
    Assignee: DURECT CORPORATION
    Inventors: Michael Sekar, Felix Theeuwes, Keith Edward Branham, John W Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
  • Publication number: 20220265830
    Abstract: The present disclosure provides long-acting formulations and vehicles, methods of making the same and methods of using the same.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Applicant: DURECT CORPORATION
    Inventors: Susan AUTIO, Keith Edward BRANHAM, James A. FILICE, John W. GIBSON, John J. LEONARD, James MATRIANO, Whitney MORO, Michael SEKAR, Chelsea Alexandra SNYDER, Robert G. STRICKLEY, Raju SUBRAMANIAN, Felix THEEUWES, Monica TIJERINA, Jeremy C. WRIGHT, Su II YUM, Faye XU
  • Publication number: 20220257619
    Abstract: The present disclosure provides long-acting formulations of tenofovir alafenamide, methods of making the same and methods of using the same.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 18, 2022
    Inventors: Susan Autio, Keith Edward Branham, James A. Filice, John W. Gibson, John J. Leonard, James Matriano, Whitney Moro, Michael Sekar, Chelsea Alexandra Snyder, Robert G. Strickley, Raju Subramanian, Felix Theeuwes, Monica Tijerina, Jeremy C. Wright, Su Il Yum, Faye Xu
  • Publication number: 20210322517
    Abstract: The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. In some cases, the composition includes sucrose acetate isobutyrate, biodegradable polymer, hydrophobic solvent, and a complex comprising a counterion and beneficial agent, such as protein, peptide, nucleic acid, or small molecular weight compound. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 21, 2021
    Applicant: DURECT CORPORATION
    Inventors: William Van Osdol, Su Il Yum, Felix Theeuwes, Michael Sekar, John W Gibson, Keith Edward Branham, Huey-Ching L. Su
  • Publication number: 20210169902
    Abstract: Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 10, 2021
    Inventors: Shunlin Ren, WeiQi Lin, James E. Brown, Felix Theeuwes, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Huey-Ching Su, Wilma Tamraz
  • Publication number: 20210128598
    Abstract: The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.
    Type: Application
    Filed: October 19, 2020
    Publication date: May 6, 2021
    Applicant: Durect Corporation
    Inventors: Michael Sekar, SuIl Yum, Felix Theeuwes, William Van Osdol
  • Publication number: 20210121467
    Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 29, 2021
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Felix THEEUWES, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
  • Publication number: 20210046091
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Application
    Filed: August 3, 2020
    Publication date: February 18, 2021
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Publication number: 20210038731
    Abstract: The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 11, 2021
    Applicant: Durect Corporation
    Inventors: Michael Sekar, Felix Theeuwes, Keith Edward Branham, John W. Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
  • Patent number: 10786517
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 29, 2020
    Assignees: Durect Corporation, Virginia Commonwealth University
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Patent number: 10758623
    Abstract: The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: September 1, 2020
    Assignee: DURECT CORPORATION
    Inventors: Michael Sekar, Felix Theeuwes, Keith E Branham, John Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
  • Publication number: 20200101073
    Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
    Type: Application
    Filed: September 3, 2019
    Publication date: April 2, 2020
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. Wright, Felix Theeuwes, John W. Gibson, Keith E. Branham, Stefania Sjobeck
  • Publication number: 20190374554
    Abstract: Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 1, 2017
    Publication date: December 12, 2019
    Inventors: Shunlin Ren, WeiQi Lin, James E. Brown, Felix Theeuwes, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Huey-Ching Su, Wilma Tamraz
  • Publication number: 20190350945
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Application
    Filed: March 28, 2019
    Publication date: November 21, 2019
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin